Loading...
Loading...
CARA| Name | Value |
|---|---|
| Revenues | 6.2M |
| Cost of Revenue | 2.6M |
| Gross Profit | 3.6M |
| Operating Expense | 31.2M |
| Operating I/L | -27.6M |
| Other Income/Expense | 1.0M |
| Interest Income | 1.0M |
| Pretax | -26.7M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | -25.7M |
Cara Therapeutics, Inc. is a biopharmaceutical company specializing in developing and commercializing chemical entities that target pruritus and pain by selectively focusing on kappa opioid receptors. Its lead product, KORSUVA (difelikefalin) injection, is designed to treat moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company's product pipeline includes Oral KORSUVA for various pruritus indications, such as atopic dermatitis, chronic kidney disease, chronic liver disease, and notalgia paresthetica. Cara Therapeutics generates revenue through the development, manufacturing, and commercialization of its drug products, including through license agreements with pharmaceutical companies in Japan and South Korea.
